30 closest matches · ranked by relevance
Mesial Temporal Lobe Epilepsy
Primary: Safety and Tolerability of Low Frequency Stimulation of the Fornix With Regards to Memory Function — 0; 0 Participants
Epilepsy, Temporal Lobe
Primary: Self-reported Seizure Frequency — 6.4 seizure days per 4 weeks
Temporal Lobe Epilepsy
Primary: Incidence of Qualifying Adverse Events — 7.9 percentage of participants
Epilepsy
Primary: The Change Scores in Memory Measures From Baseline to Post-treatment/Placebo Will be Compared Between the Memantine Treatment and Placebo Groups. — 1.00; 1.78; 4.38…
Epilepsy
Primary: Functional Connectivity
Epilepsy
Primary: Completed MEG — 1 participants
Lennox-Gastaut Syndrome
Primary: Number of Seizure After Treatment by tDCS — 80.67; 93.43; 35.53; 93.14 seizures — p=<0.05
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04
Epilepsies, Partial
Primary: 50% Responder Rate After Active rTMS Treatment Compared With Placebo Treatment — 0; 0; 0; 0 participants
Epilepsy
Primary: Primary Analysis: Change in Seizure Rate — -40.4; -14.5 Percentage change from baseline — p=0.0017
Epilepsy · Depressions, Refractory
Primary: Change in Seizure Frequency Expressed as the Average Number of Seizures Experienced by All Participants and Recorded at Specified Time Points Throughout the Study…
Major Depressive Disorder
Primary: Depression Severity — 22.5; 12.0; 14.1 score on a scale — p=0.04
Mild Cognitive Impairment
Primary: Correction Rate in Memory Association Recall — .106; .031 units on a scale
Focal Epilepsy
Primary: Intensity of the MRI Signal in the Left Temporal Precentral Zone — 1.06; 1.04 ratio
Epilepsy
Primary: To Determine if the Frequency of Premenstrual Dysphoric Disorder Differs Among Various Antiepileptic Drug Monotherapies. — 0; 0; 0; 2 Participants
Epilepsy
Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05
Meniere's Disease · Ménière's Vertigo · Vertigo, Intermittent
Primary: Change in Ménière's Vertigo Attack Frequency Between Lamotrigine and Placebo Group — 18.88; 18.00; 13.50; 4.57 Average Total Number of Vertigo Attacks — p=0.5618
Epilepsy · Schizophrenia · Schizoaffective Disorder
Primary: Change in Montgomery Asberg Depression Rating Scale (MADRS) — 16.75; 22.94; 11.21; 21.81 score on a scale — p=0.036
Primary Progressive Aphasia
Primary: Connectivity Measures of the Left TGd, 55b, and STV Parcellations at Baseline and Post-treatment — -.06; .03; -.01 correlation
Epilepsy · Tuberous Sclerosis Complex · Focal Cortical Dysplasia
Primary: Number of Patients With Adverse Events — 0; 0 Participants
Alzheimer Disease
Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections
Alzheimer's Disease
Primary: Changes in Executive Function as Measured by the NIH EXAMINER Computer Battery — -0.06; -0.14 score on a scale — p=0.55
Depression · Unipolar Depression · Treatment Resistant Depression
Primary: Remission of Depression on the Hamilton Rating Scale for Depression-24 Item (HRSD-24) — 25; 30 Participants
Depression · Major Depressive Episode · Bipolar Disorder
Primary: Hamilton Rating Scale for Depression, 24-Item (HRSD-24) — 22.625; 15.375 units on a scale
Epilepsy
Primary: Sleep Latency Wakefulness After Sleep Onset (WASO) — 42.3; 57.3 minutes/night
Epilepsy · Seizure Disorders
Primary: 50% Responder Rate — 40.5; 15.6 percentage of participants
Alzheimer's Disease · Seizures
Primary: Number of Participants With Evaluable fMRI Scans — 9; 9; 9; 9 participants
Epilepsy
Primary: Average Distance Between Positive Motor Mapping Sites of DCS
Schizophrenia; Psychosis
Primary: Hippocampal Activity (Arterial Spin Labeling [ASL] Study) After Levetiracetam (LEV) — 28.3; 27.1; 28.0; 28.5 ml/100g/min
Epilepsy
Primary: Feasibility of Microelectrode Technology to Isolate Place Responsive Neurons in the Human Hippocampus as Measured by the Number of Place Responsive Neurons. — 79 place…